Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer
JNCI: Journal of the National Cancer Institute · 01.12.2025 · 117 (12) · 2591-2597
DOI: 10.1093/jnci/djaf271 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 19.09.2025. Verfasst von Emily A Vertosick und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Swedish Cancer Society, Swedish Prostate Cancer Foundation, NCI NIH HHS.
Abstract (Originalsprache)
Background
We investigated the natural history of the relationship between prostate-specific antigen (PSA) at age 60 years and lifetime risk of prostate cancer death in an unscreened cohort followed for 40 years in the Malmö Preventive Project. We also investigated whether percent-free PSA could risk-stratify men with low PSAs.
Methods
The cohort included 1162 men aged 58-62 years at blood draw in 1981-1982, with 1151 deaths by December 31, 2020. Total and free PSA were measured for 130 men with prostate cancer and 517 without prostate cancer. Lorenz curves were calculated for life years lost to prostate cancer by baseline PSA level.
Results
Total PSA at age 60 years remained highly predictive for full lifetime risk of lethal prostate cancer (C index = 0.87, 95% confidence interval [CI] = 0.82 to 0.92). More than half of the life years lost to prostate cancer in this cohort were in men who had a PSA above 4.0 ng/ml (59%, 95% CI = 54% to 63%) at age 60 years, with 85% (95% CI = 81% to 89%) and 92% (95% CI = 90% to 94%) in men with a PSA above 2.0 ng/ml and above 1.0 ng/ml, respectively. Percent-free PSA did not aid risk stratification in men with low PSA.
Conclusions
Men with a PSA below 1-2 ng/ml at age 60 years are at low risk for lethal prostate cancer and do not require further PSA screening. Unlike a proven role in men with elevated PSA, percent-free PSA is not useful in informing the decision to stop or continue further PSA screening for men with a PSA below 2 ng/ml at age 60 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
- Department of Clinical Sciences, Lund University, Malmö, Sweden.
- Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, United States.
- Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, United States.
- Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden.
- Department of Translational Medicine, Division of Urological Cancers, Medical Faculty, Lund University, Lund, Sweden.
ORCID-Profile: Emily A Vertosick, Andrew Vickers, Anders Bjartell, Hans Lilja
Förderung
- Swedish Cancer Society
- Swedish Prostate Cancer Foundation
- NCI NIH HHS
- Swedish Scientific Council
- NIH HHS
- Prostatacancerförbundet
- Cancer Center Support
- National Institutes of Health
Zitieren
APA
Vertosick, E. A., Vickers, A., Dahlin, A., Ulmert, D., Carlsson, S. V., Eastham, J., Bjartell, A., & Lilja, H. (2025). Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer. JNCI: Journal of the National Cancer Institute, 117(12), 2591-2597. https://doi.org/10.1093/jnci/djaf271
Vancouver
Vertosick EA, Vickers A, Dahlin A, Ulmert D, Carlsson SV, Eastham J, et al. Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer. JNCI: Journal of the National Cancer Institute. 2025;117(12):2591-2597. doi:10.1093/jnci/djaf271
BibTeX
@article{Vertosick2025,
author = {Vertosick, Emily A and Vickers, Andrew and Dahlin, Anders and Ulmert, David and Carlsson, Sigrid V and Eastham, James and Bjartell, Anders and Lilja, Hans},
title = {Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {12},
pages = {2591--2597},
doi = {10.1093/jnci/djaf271}
}
EUVIMED